Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

Name: Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)
Published: 2018
License: Public Domain

Merck Sharp & Dohme LLC · 2018

ClinicalTrials.gov · Datasets · License: Public Domain · 2018

Open Source ↗

melanoma

melanoma, programmed cell death 1, pd1, pd-1, programmed cell death-ligand 1, pdl1, pd-l1, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

Related documents